Nitanap O Tablet contains Nitazoxanide 500mg + Ofloxacin 200mg, a combination therapy designed for the treatment of gastrointestinal infections caused by both protozoal and bacterial pathogens. It helps in rapid eradication of infection, relieving associated symptoms like diarrhea, abdominal pain, and dysentery.
Nitazoxanide works by inhibiting the anaerobic energy metabolism of protozoa, while Ofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase, preventing bacterial replication. Together, they provide broad-spectrum coverage for mixed infections.
For distributors and healthcare suppliers, Nitanap O Tablet is a high-demand combination therapy, frequently used in hospitals, clinics, and community healthcare settings. Gastrointestinal infections remain prevalent, ensuring consistent year-round demand.
Adding Nitanap O Tablet to your antimicrobial and antiprotozoal therapy segment creates strong opportunities in pharmacies, hospitals, travel clinics, export markets, and third-party manufacturing. Its proven efficacy, broad therapeutic coverage, and prescriber confidence make it a valuable addition to pharmaceutical distribution portfolios.